APP and Alzheimer disease: To evaluate the effects of NUCC-0226446, NUCC-0226614, NUCC-0226646, and NDC-1173 on cognitive readouts in the AD mouse model, we treated APP/PS1 male and female mice with vehicle (10%DMSO/10%Tween80 in water) or SERCA PAMs (30 mg/kg) via oral gavage three times per week for 8 weeks, starting at 6 months of age.